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Glycogen synthase kinase-3 (GSK-3) has many cellular functions. Recent evidence
suggests that it plays a key role in certain types of synaptic plasticity, in particular
a form of long-term depression (LTD) that is induced by the synaptic activation of
N-methyl-D-aspartate receptors (NMDARs). In the present article we summarize what is
currently known concerning the roles of GSK-3 in synaptic plasticity at both glutamatergic
and GABAergic synapses. We summarize its role in cognition and speculate on how
alterations in the synaptic functioning of GSK-3 may be a major factor in certain
neurodegenerative disorders.
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INTRODUCTION
While long recognized as a critical molecular effector in the cell,
and an important target for therapeutic intervention, glycogen
synthase kinase-3 (GSK-3) has only recently been discovered to
be a key regulator of synaptic plasticity. Here we review the stud-
ies that have illuminated our understanding of how GSK-3 is
involved in long-term depression (LTD) and long-term potenti-
ation (LTP) in the hippocampus. We describe potential signaling
cascades that involve GSK-3 in neurons and how this might affect
the expression of AMPA receptors at synapses. In addition, we
describe the evidence that suggests that GSK-3 also regulates
GABA-A receptor (GABAR) trafficking. Lastly, we relate these
emerging mechanisms to cognition and propose a hypothesis of
how dysregulation of GSK-3 activity at synapses could explain
important aspects of neurodegenerative disease.
ROLE OF GSK-3 IN LTP AND LTD
Information in the brain is stored primarily as changes in the
weights of synaptic connections, via the processes of LTP and
LTD. LTP, which is a long-lasting increase in the efficiency
of synaptic transmission, is usually triggered by the synap-
tic activation of N-methyl-D-aspartate receptors (NMDARs),
though NMDAR-independent forms of LTP also exist in the
CNS (Bliss and Collingridge, 1993). LTD, which is the coun-
terpart of LTP, can also be induced by the synaptic activa-
tion of NMDA receptors (NMDAR-LTD). Other forms of LTD
also exist, such as those triggered by the synaptic activation
of metabotropic glutamate receptors (mGluRs) and muscarinic
receptors (mAChRs) (Collingridge et al., 2010). Multiple mecha-
nisms exist to express the alteration in synaptic efficiency, includ-
ing changes in the probability of neurotransmitter release and
alterations in the function of postsynaptic receptors. With respect
to NMDAR triggered synaptic plasticity, the most extensively
investigated mechanisms involve alterations in the number of
α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid recep-
tors (AMPARs) expressed at synapses, caused via alterations in
AMPAR trafficking (Collingridge et al., 2004).
We found that inhibition of GSK-3 prevented the induction of
NMDAR-LTD (Peineau et al., 2007). This effect was observedwith
six structurally distinct inhibitors, at the appropriate concentra-
tion range for an action on GSK-3 (Peineau et al., 2007, 2009). In
contrast, inhibition of a large number of other serine/threonine
(Ser/Thr) protein kinases did not affect NMDAR-LTD (Figure 1).
This suggests that GSK-3 is likely to be one of a small number of
Ser/Thr protein kinases involved in this form of synaptic plastic-
ity. It is not unique, however, since we have more recently also
found a role for PI3Kγ, a dual Ser/Thr protein kinase and lipid
kinase, in NMDAR-LTD (Kim et al., 2011). Furthermore, a role
for tyrosine phosphorylation in NMDAR-LTD has been estab-
lished (Ahmadian et al., 2004; Hayashi and Huganir, 2004) and
recent evidence suggests that the tyrosine kinase Janus kinase 2
(JAK2) is required for the induction of NMDAR-LTD (Nicolas
et al., 2012). Therefore, GSK-3 is one component of a complex
phosphorylation cascade involved in NMDAR-LTD.
As described elsewhere, the isoform involved in NMDAR-
LTD is likely to be GSK-3β, though a complementary role of
GSK-3α cannot be discounted. Of the forms of synaptic plas-
ticity that have been examined, GSK-3 is specifically involved
in NMDAR-LTD (Figure 2). Thus, pharmacological inhibition of
GSK-3 has no effect on NMDAR-LTP, depotentiation, or mGluR-
LTD at CA3-CA1 synapses (Peineau et al., 2007). Of course,
a role in one or more of the several other forms of synaptic
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FIGURE 1 | GSK-3 inhibitors block the induction of NMDAR-LTD.
(A) Family tree of Ser/Thr protein kinases in the human genome
(modified from Manning et al., 2002). The two isoforms of GSK-3
(α and β) are highlighted in green. The kinases that were excluded
from having a role in the induction of NMDAR-LTD, based on inhibitor
studies reported in Peineau et al. (2007, 2009), are highlighted in yellow.
(B) Control NMDAR-LTD (top) and its block by the GSK-3 inhibitor
CT99021 (bottom). (C) Block of the induction of NMDAR-LTD by six
different GSK-3 inhibitors. See Peineau et al. (2007, 2009) for more
details.
plasticity at this or other synaptic pathways in the CNS cannot be
discounted.
Although inhibition of GSK-3β has no effect on NMDAR-LTP,
over-expression of GSK-3β blocks LTP (Hooper et al., 2007; Zhu
et al., 2007). In addition, induction of LTP inhibits the activity of
GSK-3β (Hooper et al., 2007; Peineau et al., 2007), suggesting that
LTP and LTD may interact via a pathway involving GSK-3β that
acts as a molecular switch.
ROLE OF GSK-3 IN METAPLASTICITY
Metaplasticity refers to changes in the ability of synapses to
undergo plasticity after a previous synaptic or modulatory
event, sometimes called “priming” (see review by Abraham and
Bear, 1996). Several different forms of metaplasticity have been
described so far. The prototypic form of metaplasticity is depo-
tentiation, which is a form of LTD that can only be induced
following the induction of LTP (where it reverses the potentia-
tion to the baseline state; as reviewed by Collingridge et al., 2010).
Another form of metaplasticity is where the prior activation of
NMDARs can inhibit the subsequent induction of NMDAR-LTP
(Coan et al., 1989; Huang et al., 1992). The findings, described
above, that NMDAR-LTP can inhibit the activity of GSK-3β and
that GSK-3β is required for NMDAR-LTD suggested the existence
of another form of metaplasticity whereby LTP regulates LTD.
We explored this prediction experimentally and found that
LTP did, indeed, potently inhibit NMDAR-LTD. The priming was
induced by a protocol that could induce NMDAR-LTD but the
induction of LTP per se was not a prerequisite. Indeed, many
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FIGURE 2 | The role of GSK-3 in NMDAR-LTD. (A) Signaling pathways
involved in the induction of NMDAR-LTD and the regulation of GSK-3β.
(B) Signaling pathway by which NMDAR-LTP can inhibit NMDAR-LTD.
(C) Potential downstream effectors of GSK-3β in NMDAR-LTD. (See text for
details).
experiments were performed under conditions in which LTP
was deliberately absent, due to the phenomenon of washout
(Malinow and Tsien, 1990), so as to eliminate the potentially
confounding situation of depotentiation. In other experiments
depotentiation was blocked by an mGluR antagonist. We found
that the LTP stimulus (priming stimulus) completely prevented
the induction of NMDAR-LTD immediately following the prim-
ing. Maximal inhibition of NMDAR-LTD lasted for about 20min,
where after there was a slow recovery of the ability to induce
NMDAR-LTD such that after approximately 1 h the ability to
induce NMDAR-LTDwas fully restored. Themechanism of prim-
ing involved activation of NMDARs since it was prevented if
an NMDAR antagonist was present during the priming. It also
involved the canonical pathway for inhibition of GSK-3, namely
phosphoinositide 3-kinase (PI3K) and Akt/PKB (protein kinase
B; Figure 2B; Embi et al., 1980; Peineau et al., 2007).
UPSTREAM REGULATION OF GSK-3 IN SYNAPTIC
PLASTICITY
The GSK-3 α and β isoforms are ubiquitous Ser/Thr kinases
belonging to the CMGC family of protein kinases that act as key
enzymes regulating various cellular signaling pathways. GSK-3
function is modulated through multiple regulatory mechanisms
by protein-protein interactions, subcellular localization, prim-
ing/substrate specificity, and proteolytic cleavage, which have
been recently reviewed by others (Hur and Zhou, 2010; Medina
and Wandosell, 2011 and reviewed in this Special Topic by
Kaidanovich-Beilin and Woodgett, 2011). Within these levels of
functional regulation, phosphorylation and dephosphorylation
play prominent roles.
Under certain biochemical conditions such as growth fac-
tor deprivation, the mammalian target of rapamycin complex
1(mTORC1)-S6K1 signaling can alternatively regulate and inhibit
GSK-3 activity by Ser21/9 phosphorylation (Cohen and Frame,
2001; Zhang et al., 2006). There are also several other kinases
such as Erk, ZAK1, MEK1/2, Pyk-2, and Fyn kinases that also
have been described to interact with GSK-3 and regulate its func-
tion in other cell types (Kim et al., 1999, 2002; Lesort et al.,
1999; Hartigan et al., 2001; Ding et al., 2005). However, the
extent to which these regulatory processes occur in neurons and,
more specifically, are involved in synaptic plasticity is largely
unexplored.
We have described an upstream phosphorylation/dephos-
phorylation-dependent regulation of GSK-3β activity that is
involved in NMDAR-LTD (Figure 2A). We cannot discount an
additional role of GSK-3α, but focus on the β isoform in this
review. Thus far, three sites of phosphorylation have been iden-
tified on GSK-3β: Ser9 (Sutherland et al., 1993), Tyr216 (Hughes
et al., 1993), and Ser389 (Thr 390 in humans; Thornton et al.,
2008) and have also been shown to be important regulatory
elements in neurons. It should be noted that while regula-
tion at Thr43 has been demonstrated in other cell types (Ding
et al., 2005; Thornton et al., 2008), it remains to be explored
in neurons.
The basal activity of GSK-3β is dependent on phosphorylation
on Tyr216 (Hughes et al., 1991, 1993). The mechanism by which
this Tyr residue becomes phosphorylated is still under debate. It
is unclear whether there is an autophosphorylation mechanism
(Cole et al., 2004; Lochhead et al., 2006) and/or a regulation
by tyrosine kinases such as Fyn (Lesort et al., 1999) or Pyk2
(Hartigan et al., 2001). In resting neurons, Tyr216 is phospho-
rylated, and thus, GSK-3β is constitutively active (Hur and Zhou,
2010).
The main way neurons regulate GSK-3β activity is by con-
trolling the phosphorylation level of Ser9 (for review see Doble
and Woodgett, 2003). The phosphorylation of this site inhibits
enzymatic activity. At least eight distinct signaling pathways have
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been identified as a regulator of the Ser9 phosphorylation state
(Figure 3). Seven of them are inhibitory and mediated by kinases.
These are the Akt pathway (Hong and Lee, 1997), which we have
shown to be important inmediating the phosphorylation of GSK-
3β during LTP (Peineau et al., 2007; Figure 2B). In addition,
CaMKII has been shown to phosphorylate and inhibit GSK-3 in
neurons, where it functions in a pro-survival manner (Song et al.,
2010). Phosphorylation of GSK-3β (and not GSK-3α) by classi-
cal protein kinase C (PKC) isotypes (α, β1, β2, and γ) results in
its inactivation (Espada et al., 2009; Ortega et al., 2010) and may
protect neurons from Aβ toxicity (Garrido et al., 2002). In addi-
tion, protein kinase A (PKA; Li et al., 2000; O’Driscoll et al., 2007;
Shelly et al., 2010, 2011), PrkG1 (Zhao et al., 2009), p90 ribosomal
protein S6 kinase (RSK; Valerio et al., 2006) and Integrin-linked
kinase (ILK; Naska et al., 2006) also regulate GSK-3 activity in
neurons. Interestingly, ILK directly interacts and phosphorylates
GSK-3β and also phosphorylates Akt to inhibit GSK-3β indirectly
(Delcommenne et al., 1998).
A third site to regulate GSK-3β activity has been recently
identified. The highly enriched neuronal enzyme p38 mitogen-
activated protein kinase (p38MAPK) was found to phosphorylate
GSK-3β at Ser389 (Thr390 in humans) causing inhibition of its
activity similar to that of inhibition via Ser9 (Thornton et al.,
2008). Inhibition of GSK-3β via p38MAPK stimulates accumu-
lation of β-catenin.
Only one pathway has been shown to stimulate GSK-3β activ-
ity in neurons and is mediated by protein phosphatase 1 (PP1)
removing the phosphate group on Ser9 (Bennecib et al., 2000;
Morfini et al., 2004). Noteworthy, a positive loop between PP1
and GSK-3β has been identified (Szatmari et al., 2005). We have
observed a marked activation of GSK-3β during NMDAR-LTD
via dephosphorylation of Ser9 mediated by PP1 (Peineau et al.,
FIGURE 3 | Potential regulators of GSK-3 β in neurons (see text for
details).
2007). However, the involvement of additional pathways that
activate GSK-3β activity during NMDAR-LTD may also exist.
Indeed, in other systems there are a variety of phosphatases,
which dephosphorylate and disinhibit GSK-3 activity (Wera and
Hemmings, 1995). In terms of the regulation by PP1, it is
likely that during NMDAR-LTD this involves Ca2+ entry through
NMDARs, binding of Ca2+ to calmodulin, activation of PP2B
(calcineurin) leading to dephosphorylation of Inhibitor 1 (I-1)
which in turn leads to activation of PP1 (Figure 2A). This path-
way has been shown to be important for NMDAR-LTD (Mulkey
et al., 1994).
DOWNSTREAM EFFECTORS OF GSK-3 IN SYNAPTIC
PLASTICITY
How GSK-3β activation contributes to the expression of
NMDAR-LTD remains unknown. Given that the activation of
NMDARs and endocytosis of AMPARs are, respectively, involved
in the induction and expression of LTD, it appears quite reason-
able to investigate if GSK-3β can exert its actions by regulating
either or both of the processes. Indeed, one study has reported
a GSK-3 activity dependent rapid internalization of NMDARs
(Chen et al., 2007). Thus, LTP might inhibit LTD by regulat-
ing the levels of NMDARs that are required for LTD induction.
However, in this case, one would expect to see a rapid depres-
sion of NMDAR-mediated synaptic transmission as a result of a
rapid internalization of the receptors following LTP induction.
However, most studies of LTP that have monitored NMDAR-
mediated synaptic transmission have reported LTP [e.g., (Bashir
et al., 1991)] rather than a transient depression. Thus, further
work is needed to establish the extent to which the regulation
of NMDAR trafficking by GSK-3β accounts for its involvement
in synaptic plasticity. Any inhibition of NMDAR activity by
GSK-3 antagonists is highly unlikely to have accounted for the
inhibition of NMDAR-LTD in our experiments (Peineau et al.,
2007). First, the effects observed on NMDARs were typically
around 20% inhibition and this may be too small to prevent
NMDAR-LTD induction. Indeed, whilst we observed a com-
plete block of NMDAR-LTD there was sufficient NMDAR acti-
vation for NMDAR-LTP to be induced (Peineau et al., 2007).
GSK-3β affects not only the induction, but also the expres-
sion of LTD as lithium was able to fully block NMDAR-LTD
even when applied after the induction protocol (Peineau et al.,
2007). Thus, even if the inhibition of NMDAR function may con-
tribute to the effects under certain circumstance it cannot be the
sole mechanism.
Wei and colleague (2010) recently showed that constitutive
GSK-3β activity enhances basal AMPAR endocytosis. They found
that either pharmacological inhibition or knockdown of the pro-
tein resulted in a decrease in mEPSC amplitude in cultured
hippocampal neurons (Wei et al., 2010). They went on to demon-
strate that internalization of AMPARs is via enhanced activity of
Rab5 and is dependent on phosphorylation of guanine nucleotide
dissociation inhibitor (GDI) at Ser45. They also showed that the
effects of inhibition of GSK-3 and insulin occluded, suggesting
that insulin-induced endocytosis of AMPARs (Man et al., 2000)
is due to inhibition of GSK-3 (Figure 2C). At first glance these
observations seem at variance with the reports that inhibition
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of GSK-3β blocks NMDAR-LTD (Peineau et al., 2007, 2009) and
Aβ-mediated inhibition of LTP (Jo et al., 2011) without affecting
baseline AMPAR-mediated transmission. Although the effects on
mEPSC amplitude where small (15–18%) they should have been
detected as a small reduction in baseline transmission, but this
was never observed. A potential explanation for these differences
is the levels of activity of GSK-3β in the two preparations. As
described above, GSK-3β is tightly regulated by inhibition on
Ser9 by a variety of signaling pathways and is actively suppressed
by LTP (via the PI3K/Akt pathway). Loss of any of these regu-
latory systems might result in a higher constitutive activity of
GSK-3 in cultured dissociated neurons. It, therefore, remains
to be determined whether endocytosis of AMPARs during LTD
involves GSK-3β-dependent phosphorylation of GDI and activa-
tion of Rab5.
We have observed a complex formation between GSK-3β and
AMPARs and found that the activity of GSK-3β within this com-
plex is regulated by LTP (Peineau et al., 2007). These results
strongly suggest that GSK-3β may regulate AMPAR function or
trafficking, thereby affecting the expression of LTD. Consistent
with this conjecture, a recent study (Du et al., 2010) has reported
that GSK-3β inhibition prevented the NMDA-induced AMPAR
endocytosis in a model of chemical LTD (Collingridge et al.,
2010). How GSK-3β is involved in AMPAR endocytosis during
LTD expression remains to be established. Given that a serine
phosphorylation of the GluA2 subunit has been reported to be
critical for receptor endocytosis during LTD (Kim et al., 2001a;
Chung et al., 2003), GSK-3β may play an important role in medi-
ating the expression of LTD by triggering the GluA2 phosphoryla-
tion dependent process. However, in vitro phosphorylation assays
have failed to demonstrate an ability of GSK-3β to phosphorylate
the carboxyl tail of GluA2 (authors’ unpublished observation),
suggesting that GSK-3β may phosphorylate one or more other
proteins that are required for the regulated AMPAR endocytosis.
It has been proposed that one such potential protein is kinesin
light chain 2 (KLC2; Du et al., 2010), a key molecule of the
kinesin cargo delivery system, which may be involved in the trans-
port of AMPAR-containing membrane-bound vesicles in neurons
(Setou et al., 2002) and has previously been demonstrated as a
target of neuronal GSK-3 (Morfini et al., 2002). In this study,
Du et al. (2010) have shown that GSK-3β phosphorylation of
KLC2 promotes its dissociation from the AMPAR/KLC2 protein
complex (Figure 2C). This suggests that GSK-3 phosphoryla-
tion of KLC2 may lead to the dissociation of AMPAR-containing
vesicles from the kinesin cargo system, thereby affecting the traf-
ficking of AMPARs in neurons. To directly demonstrate that
phosphorylation of KLC2 is one of the critical steps in GSK-3β
promoted LTD, the authors developed a membrane permeable
FIGURE 4 | Dysregulation of GSK-3 as a potential causal factor in
neurodegeneration. NMDAR-LTD results in a reduction in the number of
AMPARs at synapses. It can lead to the removal of all AMPARs (termed
“silencing”) and synapse elimination, via the process of synaptosis (localized
apoptosis). This process is likely to be prominent early in development,
where it may be important for the pruning of unwanted synaptic connections.
During adulthood it may be more tightly regulated so that LTD involves mainly
reductions in synaptic efficacy rather than the elimination of synapses. In
particular, synapses that experience regular LTP will have the activity of
GSK-3 dampened, by virtue of the PI3K-Akt pathway. In response to stressors
(genetic, epigenetic, or environmental) the same mechanisms may be
rekindled, resulting in unwanted synaptic elimination. In this example, the
dysregulation of GSK-3β activity is due to activation of caspases leading to
cleavage of Akt.
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peptide TAT-KLCpCDK, a specific inhibitor for KLC2 phospho-
rylation by GSK-3β, and showed that by preventing GSK-3β
phosphorylation of KLC2, it inhibited both AMPAR endocyto-
sis and the expression of hippocampal CA1 LTD. Thus, this study
has provided strong evidence that KLC2 may be a cellular target
of GSK-3β capable of regulating AMPA receptor trafficking and
hence synaptic plasticity. Of course, GSK-3βmay also affect other
components of the AMPAR endocytosis pathway. In addition
to AMPAR endocytosis, GSK-3β may influence LTD expression
by regulating other processes, some of which are illustrated in
Figure 2C. Other potential targets include tau and presenilin-1,
as well as transcription factors that may be involved in the protein
synthesis dependent phase of NMDAR-LTD (Manahan-Vaughan
et al., 2000).
ROLE IN PATHOLOGICAL SYNAPTIC PLASTICITY
A large body of evidence suggests that changes in synaptic plastic-
ity may be responsible for the cognitive deficits that are observed
in various brain disorders (Bowers et al., 2010; Goto et al.,
2010; Kasai et al., 2010; Russo et al., 2010; van Spronsen and
Hoogenraad, 2010; Proctor et al., 2011; Quartarone and Pisani,
2011; Zhuo et al., 2011). Increasing evidence suggests, addition-
ally, that alterations in various molecular components of synaptic
plasticity pathways may actually be the cause of many of these
disorders (see review by Collingridge et al., 2010). We term this
process pathological plasticity, to distinguish it from the forms
of plasticity that are utilized by the CNS during the formation
and stabilization of synaptic connections (developmental plastic-
ity) and for learning and memory (cognitive plasticity; Figure 4).
This basic premise is that NMDAR-LTD is a mechanism that is
used by the CNS to remove AMPARs from synapses and thereby
weaken the efficiency of synaptic transmission. This enables the
storage of information, and indeed there is growing evidence
that NMDAR-LTD is involved in forms of learning and mem-
ory (see review by Collingridge et al., 2010). NMDAR-LTD can
involve the removal of all AMPARs from individual synapses
(Luthi et al., 1999), via a process known as silencing. These silent
synapses can then either (1) have new AMPARs inserted via the
process of unsilencing (Isaac et al., 1995; Liao et al., 1995) or (2)
are eliminated (Bastrikova et al., 2008; Kano et al., 2008; Egashira
et al., 2010). Since NMDAR-LTD is particularly prevalent early
in development (Dudek and Bear, 1993) when there is consid-
erable pruning of superfluous synaptic connections (Rabacchi
et al., 1992; Bhatt et al., 2009), it is likely that NMDAR-LTD
is a physiological mechanism used to eliminate synapses during
development.
With respect to a molecular mechanism, we previously showed
that NMDAR triggered apoptosis, and the associated increase
in caspase-3 activity, requires AMPAR endocytosis (Wang et al.,
2004). More recently we found that NMDAR-LTD also involves
activation of a caspase cascade (Li et al., 2010). These studies
suggest that the internalization of AMPARs associated with LTD
triggers a local apoptosis. We will refer to this process as synapto-
sis, a term originally coined for the compartmentalized retraction
of synapses at the neuromuscular junction (Gillingwater and
Ribchester, 2001). After the period of synaptic pruning during
development is over and the organization of the brain is largely
complete then it makes sense that the mechanisms of synapto-
sis are down-regulated. We, therefore, assume that for most of
the normal life-span NMDAR-LTD is used more sparingly and
for mainly adjusting synaptic weights rather than for eliminating
synapses because it would be an energetically more efficient way
to store information. However, if these latent synaptosis mech-
anisms were once again awakened then synapses could be elimi-
nated. Our hypothesis is that neurodegeneration is often triggered
by just this reactivation of synaptosis, which if left unchecked
leads to apoptosis of vulnerable neuronal populations. The idea
that the weakening of connections between nerve cells may
explain dementia has been around for over 100 years. However,
the observation that GSK-3β regulates the balance between LTP
and LTD provides the basis of a molecular mechanism that gives
credence to this idea.
In terms of a molecular mechanism, we suggest that GSK-3β
is activated to enable NMDAR-LTD and that this mechanism is
especially prominent early in development for synaptic pruning.
In adulthood, whilst this mechanism may still occur it is utilized
less often so as to preserve synaptic connectivity. The ability of
NMDAR-LTP to inhibit NMDAR-LTD via GSK-3β activity pro-
vides a potential mechanism to enable this regulation. Thus, as
long as synapses are engaging LTP processes then they are pro-
tected from NMDAR-LTD by the PI3K/Akt regulatory pathway.
In other words, it is a classic case of “use it or lose it” where
this translates into “use LTP or lose the synapse” (because it is
cognitively unimportant).
Pathological plasticity could then result from any one of a
number of influences, genetic, epigenetic, or environmental, that
affect the LTD process directly or its regulation by LTP so that the
LTD mechanism becomes more actively re-engaged. As a formal
test of this hypothesis, we used the acute application of Aβ1−42.
This treatment is well known to cause a synaptic toxicity, which
is characterized by an inhibition of NMDAR-LTP and facilitation
of NMDAR-LTD (Cullen et al., 1997; Chen et al., 2000; Kim et al.,
2001b; Li et al., 2009; Shankar et al., 2008; Witton et al., 2010). We
studied the former, and tested the ability of a GSK-3β inhibitor
to prevent the effect (Jo et al., 2011). What we found was that
this inhibitor protected synapses from the deleterious effects of
Aβ, such that LTP was no longer affected. Similar observations
were made in parallel by another group using a different GSK-3
inhibitor (Shipton et al., 2011). Thus, it seems that over-activation
of GSK-3β is indeed responsible for this pathological effect on
plasticity.
Remarkably, in our study, the GSK-3β inhibitor was still fully
effective if applied after the Aβ peptide had exerted its effects
to inhibit LTP. This experiment is illustrated in Figure 5. The
implications of this finding are that the Aβ-mediated inhibi-
tion of LTP is due, at least for a while, to the increased activity
of GSK-3β. It is possible that in AD a chronic activation of
GSK-3β (Hooper et al., 2008) is responsible for the synaptosis
and consequently that GSK-3 inhibitors will reverse the cognitive
decline. Of course, GSK-3 inhibitors will have many side-effects
relating to the ubiquitous actions of this kinase throughout the
body (see other chapters in this volume). But understanding the
full cascades involved in the pathological activation of GSK-3β in
synaptosis offers the possibility of finding more specific targets.
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FIGURE 5 | The CAG cascade. (A) potential mechanism by which various
neuronal insults (exemplified here by Aβ1–42) may inhibit NMDAR-LTD
via the activation of caspase-3 (C) which, by resulting in cleavage of Akt
(A), results in persistent activation of GSK-3β (G). (B) Experimental
data in support of the “CAG” cascade hypothesis. Pooled data (from
left to right) showing LTP in two inputs, in response to high frequency
stimulation (HFS), blockade of LTP in both inputs by pre-incubation with
Aβ1–42 (500 nM, 2 h) and recovery of LTP in input two following
treatment with the GSK-3 inhibitor CT-99021 (1μM). Data re-plotted from
Jo et al. (2011).
In terms of a molecular mechanism, we found that inhibition
of caspase-3 and the prevention of the caspase-mediated cleavage
of Akt was also able to completely prevent the Aβ-mediated inhi-
bition of LTP. Thus, it seems that Aβ activates caspase-3, which
cleaves Akt to persistently activate GSK-3β and thereby trigger
synaptosis; we have termed this the CAG cascade (Figure 5). What
is not known is how Aβ activates casapse-3 to initiate the pro-
cess, though an action via mitochondria seems likely. Also the
downstream effectors of GSK-3β pathological plasticity are not
established. A role for tau is likely given that the Aβ inhibition of
LTP is prevented in the tau knockout (Shipton et al., 2011) and
since, more generally, tau is a likely effector of GSK-3β regulated
toxicity in AD (Morris et al., 2011).
ROLE IN SYNAPTIC PLASTICITY AT GABAergic SYNAPSES
In addition to playing an important role in synaptic plasticity at
glutamatergic synapses, recent evidence also suggests a role for
GSK-3β in plasticity at GABAergic synapses in the CNS.
GABAergic plasticity has been demonstrated in many brain
regions (for reviews see Gaiarsa et al., 2002; Mendez and Bacci,
2011). Some forms of GABAergic plasticity are dependent on
Ca2+ entry via stimulation of NMDARs (Wang et al., 2003a;
Marsden et al., 2007, 2010;Muir et al., 2010) and alterations in the
post-synaptic GABAR distribution (for review see Luscher et al.,
2011). Indeed, activation of calcineurin, which forms a complex
with the intracellular loop of the γ2 subunit of GABARs, may be
a critical step in the induction of GABAergic LTD (Wang et al.,
2003a). Recent work has since demonstrated that activity causes
rapid dispersion of GABAR clusters (Bannai et al., 2009) and is
dependent on Ca2+ entry and Ser327 of the γ2 subunit (Muir
et al., 2010). We have also previously shown that insulin, via the
PI3 kinase-Akt pathway, causes a rapid increase of GABAergic
synaptic transmission and concomitant LTD at glutamatergic
synapses (Wan et al., 1997; Man et al., 2000; Wang et al., 2003b).
Though GSK-3β stimulation via the insulin pathway has not yet
been demonstrated in neurons, it would not be surprising to see
that GSK-3 may regulate GABAergic transmission under these
conditions as well.
Indeed, modulation of GABAergic function, via alteration of
the scaffolding molecule gephyrin, has recently been demon-
strated under conditions of chronic treatment with GSK-3β
inhibitors (Tyagarajan et al., 2011). In this study the authors
identified Ser270 on the inhibitory scaffolding protein gephyrin
as a unique phosphorylation site targeted by GSK-3β. Mutation
of this site to an alanine residue increased both the number of
post-synaptic gephyrin clusters and the frequency of mIPSCs. The
pharmacological inhibition of GSK-3β similarly induced greater
post-synaptic clustering of gephyrin. Mechanistically, it appears
that GSK-3β phosphorylation of Ser270 may cause gephyrin to be
targeted for proteolytic degradation by the Ca2+-dependent pro-
tease calpain-1, and thus reduce gephyrin clusters and decrease
GABAergic transmission.
However, in this study it was not clear what the implica-
tions are to GABARs on the surface of the cell as the authors
did not extend their findings to look at localization of GABARs.
Thus far, α1, α2, and α3 subunits of the GABARs have been
demonstrated to interact with gephyrin (Mukherjee et al., 2011;
Tretter et al., 2008, 2011 respectively). Gephyrin appears to have
different affinities for all these receptors (Maric et al., 2011),
and strongly interacts with glycine receptors (Pfeiffer et al.,
1982). Thus, each receptor type may be affected differentially
by GSK-3β.
Wei et al. (2010) present biochemical data that β2/3 contain-
ing GABARs were increased on the cell surface within 10min
of GSK-3β inhibition, suggesting that GABAergic transmission
may be rapidly increased by the actions of this kinase. Because
the previous study used long treatments with GSK-3β inhibitors
more work is required to establish how rapid down-regulation
or up-regulation of GSK-3β affects gephyrin clustering and
GABAergic transmission.
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GSK-3β, LTD, AND THE IMPLICATIONS FOR LEARNING
ANDMEMORY
Since dysregulation of GSK-3 activity has been strongly impli-
cated in a number of mood-related disorders (Lovestone et al.,
2007; Du et al., 2010 and reviewed in this Special Topic by
Jope, 2011) as well as AD (Giese, 2009 and reviewed in this
Special Topic by Kremer et al., 2011), understanding the effects
of GSK-3β’s involvement in normal learning and memory, and
the importance of the LTD and LTP interaction in this context,
is of great interest. Spatial memory impairments on the Morris
water maze task have been demonstrated in transgenic mice with
a conditional over-expression of GSK-3β (Hernandez et al., 2002).
In another study by Engel et al. (2006), these same mice showed
significant deficits in the object recognition task, which were com-
pletely reversed when GSK-3β over-expression was restored to
normal levels (Engel et al., 2006).
More recently, Kimura and colleagues sought to elucidate the
role of GSK-3 by examining hypogene function on memory for-
mation and maintenance (Kimura et al., 2008). In adult mice
heterozygous for GSK-3β expression (GSK-3β+/−), the animals
learned the Morris water maze task at a similar rate as wild type
mice, but retrograde amnesia began to affect learning of the task
in days 3–9 suggesting that long-term memory formations were
adversely affected. Further testing of these heterozygous GSK-3β
knock-out mice, using the contextual fear conditioning (CFC)
paradigm, suggested that hypo-expression of GSK-3β affected
reconsolidationofmemory specifically. InhibitionofGSK-3βwith
the inhibitorAR-A014418beforeconsolidationorbefore reconsol-
idation in CFC showed severely disrupted reconsolidation. They
further demonstrated with western blotting that memory recon-
solidation is associated with activation of synaptosomal GSK-3β
in wild type hippocampal neurons and that intermediate levels
of GSK-3β activity were observed upon learning or in the con-
solidation state relative to naive animals. Though direct evidence
is still required, because of the role of GSK-3β activity in LTD
mechanisms, these experimentsmay indicate a greater importance
of an LTD dependent cascade in reconsolidation memory.
Periods of sleep may also enhance consolidation of certain
types of learning and memory (for reviews see Born et al., 2006;
Ribeiro, 2011). Interestingly, in a study on sleep and awake states
of plasticity, alterations in molecular, and electrophysiological
LTD correlates have also been found. The sleep state (relative
to awake state) was associated with low Ser9 phosphorylation of
GSK-3β, and hence greater activity and low GluA1 levels as well
as a long lasting depression of responses to evoked stimulation
(Vyazovskiy et al., 2008). This suggests that during sleep there is
an increase in LTD mechanisms relative to LTP mechanisms and
that this could potentially underlie the enhancement of memory
formation through improved consolidation.
CONCLUSIONS
The last few years have seen GSK-3 firmly established as a key
player in synaptic plasticity. In particular, it has been shown to be
involved in NMDAR-LTD and to be regulated during NMDAR-
LTP. We have developed the hypothesis that the ability of LTP to
inhibit LTD, via the PI3K/Akt/GSK-3β pathway, serves to stabi-
lize synapses, which would otherwise be lost through the process
of synaptosis. We argue that synapses live in a precarious state
whereby if they are not protected by LTP then they die at the
hands of LTD. This process may serve key physiological func-
tions particularly during development, where synaptic pruning
of unwanted connections is of paramount importance, but also
during adulthood. However, we postulate that pathological alter-
ations in this pathway, leading to excessive GSK-3β activity, may
actually be a causal factor in some forms of neurodegeneration.
The understanding of how GSK-3 is involved in synaptic plastic-
ity is in its infancy. Clearly, it will be important to establish a more
complete picture of howGSK-3β contributes to synaptic plasticity
in both health and disease.
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